teclistamab

Home
Ligands
teclistamab

GtoPdb Ligand ID: 12233

Synonyms: JNJ-64007957 | teclistamab-cqyv | Tecvayli®

teclistamab is an approved drug (EMA & FDA (2022))

Comment: Teclistamab (JNJ-64007957) is a bispecific IgG4 monoclonal antibody that simultaneously engages CD3 on the surface of T cells, and B-cell maturation antigen (BCMA) that is expressed on the surface of multiple myeloma (MM) cells, to induce a T cell-mediated cytotoxic immune response against the BCMA +ve cells [2].

References
1. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A et al.. (2022) Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med, 387 (6): 495-505. [PMID:35661166]
2. Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, Zhang X, Mendonça M, Majewski N, Nanjunda R et al.. (2020) Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv, 4 (18): 4538-4549. [PMID:32956453]
3. (2023) Teclistamab Approved for Myeloma. (News in Brief). Cancer Discov, 1 (13): OF1. DOI: 10.1158/2159-8290.CD-NB2022-0066

References

1. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A et al.. (2022)
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med, 387 (6): 495-505. [PMID:35661166]

2. Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, Zhang X, Mendonça M, Majewski N, Nanjunda R et al.. (2020)
Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
Blood Adv, 4 (18): 4538-4549. [PMID:32956453]

3. (2023)
Teclistamab Approved for Myeloma. (News in Brief).
Cancer Discov, 1 (13): OF1. DOI: 10.1158/2159-8290.CD-NB2022-0066